Adam R. Kalbermatten net worth and biography

Adam Kalbermatten Biography and Net Worth

President and Chief Executive Officer of KORU Medical Systems

Adam Kalbermatten joined KORU Medical Systems as Chief Commercial Officer in July 2025 and was appointed President in March 2026. Effective July 1, 2026, he was appointed Chief Executive Officer and President. Adam brings more than 20 years of commercial leadership experience across the medical device and pharmaceutical industries. Adam has a proven track record of accelerating growth, scaling businesses, and building high-performing teams, all while delivering innovative, customer-centric solutions.

Prior to KORU, Adam served as Vice President and General Manager of the Advanced Drug Delivery Systems business at Becton Dickinson (“BD”). He previously served as Chief Executive Officer of ZebraSci, a drug-device combination product development firm, where he led a successful turnaround and growth strategy, resulting in the company’s acquisition by BD. Earlier in his career, Adam held global leadership and engineering roles at both Terumo Corporation and BD.

Adam holds a Bachelor of Engineering in Mechanical Engineering and a Master of Engineering in Engineering Management from Stevens Institute of Technology and an MBA from Columbia Business School.

What is Adam R. Kalbermatten's net worth?: The estimated net worth of Adam R. Kalbermatten is at least $1.21 million as of June 11th, 2026. Mr. Kalbermatten owns 312,500 shares of KORU Medical Systems stock worth more than $1,206,250 as of July 22nd. This net worth approximation does not reflect any other assets that Mr. Kalbermatten may own. Learn More about Adam R. Kalbermatten's net worth.
How do I contact Adam R. Kalbermatten?: The corporate mailing address for Mr. Kalbermatten and other KORU Medical Systems executives is 24 CARPENTER RD, CHESTER NY, 10918. KORU Medical Systems can also be reached via phone at (845) 469-2042 and via email at [email protected]. Learn More on Adam R. Kalbermatten's contact information.
Has Adam R. Kalbermatten been buying or selling shares of KORU Medical Systems?: Adam R. Kalbermatten has not been actively trading shares of KORU Medical Systems during the last quarter. Most recently, on Thursday, June 11th, Adam R. Kalbermatten bought 12,500 shares of KORU Medical Systems stock. The stock was acquired at an average cost of $3.94 per share, with a total value of $49,250.00. Following the completion of the transaction, the insider now directly owns 312,500 shares of the company's stock, valued at $1,231,250. Learn More on Adam R. Kalbermatten's trading history.
Who are KORU Medical Systems' active insiders?: KORU Medical Systems' insider roster includes Thomas Adams (Chief Financial Officer), James Beck (Director), Adam Kalbermatten (President and Chief Executive Officer), Joseph Manko, Jr. (Director), Christopher Pazdan (Chief Operating Officer), and Eric Schiller (Chief Technology Officer). Learn More on KORU Medical Systems' active insiders.
Are insiders buying or selling shares of KORU Medical Systems?: In the last twelve months, KORU Medical Systems insiders bought shares 4 times. They purchased a total of 28,000 shares worth more than $109,430.00. The most recent insider tranaction occured on June, 11th when insider Adam R Kalbermatten bought 12,500 shares worth more than $49,250.00. Insiders at KORU Medical Systems own 18.5% of the company. Learn More about insider trades at KORU Medical Systems.
Information on this page was last updated on 6/11/2026.

Adam R. Kalbermatten Insider Trading History at KORU Medical Systems

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/11/2026	Buy	12,500	$3.94	$49,250.00	312,500

Adam R. Kalbermatten Buying and Selling Activity at KORU Medical Systems

KORU Medical Systems Company Overview

KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.

Today's Range

Now: $3.86

$3.83

$4.03

50 Day Range

MA: $4.12

$3.83

$4.60

2 Week Range

Now: $3.86

$3.20

$6.61

Volume

148,768 shs

Average Volume

160,699 shs

Market Capitalization

$177.30 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41